Pathophysiology  ||| S:0 E:16 ||| NNP
of  ||| S:16 E:19 ||| IN
fibromyalgia  ||| S:19 E:32 ||| VBG
This  ||| S:32 E:37 ||| DT
article  ||| S:37 E:45 ||| NN
reviews  ||| S:45 E:53 ||| VBZ
the  ||| S:53 E:57 ||| DT
biologic ||| S:57 E:65 ||| NN
,  ||| S:65 E:67 ||| ,
genetic ||| S:67 E:74 ||| JJ
,  ||| S:74 E:76 ||| ,
and  ||| S:76 E:80 ||| CC
environmental  ||| S:80 E:94 ||| JJ
factors  ||| S:94 E:102 ||| NNS
that  ||| S:102 E:107 ||| WDT
may  ||| S:107 E:111 ||| MD
contribute  ||| S:111 E:122 ||| VB
to  ||| S:122 E:125 ||| TO
the  ||| S:125 E:129 ||| DT
pathophysiology  ||| S:129 E:145 ||| NN
of  ||| S:145 E:148 ||| IN
fibromyalgia ||| S:148 E:160 ||| NN
.  ||| S:160 E:162 ||| .
As  ||| S:162 E:165 ||| IN
an  ||| S:165 E:168 ||| DT
affective  ||| S:168 E:178 ||| JJ
spectrum  ||| S:178 E:187 ||| NN
disorder ||| S:187 E:195 ||| NN
,  ||| S:195 E:197 ||| ,
fibromyalgia  ||| S:197 E:210 ||| NNS
may  ||| S:210 E:214 ||| MD
share  ||| S:214 E:220 ||| VB
these  ||| S:220 E:226 ||| DT
causal  ||| S:226 E:233 ||| JJ
factors  ||| S:233 E:241 ||| NNS
with  ||| S:241 E:246 ||| IN
a  ||| S:246 E:248 ||| DT
number  ||| S:248 E:255 ||| NN
of  ||| S:255 E:258 ||| IN
related  ||| S:258 E:266 ||| JJ
and  ||| S:266 E:270 ||| CC
co-occurring  ||| S:270 E:283 ||| JJ
pain  ||| S:283 E:288 ||| NN
conditions ||| S:288 E:298 ||| NNS
,  ||| S:298 E:300 ||| ,
such  ||| S:300 E:305 ||| JJ
as  ||| S:305 E:308 ||| IN
irritable  ||| S:308 E:318 ||| JJ
bowel  ||| S:318 E:324 ||| JJ
syndrome  ||| S:324 E:333 ||| NN
or  ||| S:333 E:336 ||| CC
temporomandibular  ||| S:336 E:354 ||| JJ
disorder ||| S:354 E:362 ||| NN
.  ||| S:362 E:364 ||| .
There  ||| S:364 E:370 ||| EX
is  ||| S:370 E:373 ||| VBZ
strong  ||| S:373 E:380 ||| JJ
evidence  ||| S:380 E:389 ||| NN
that  ||| S:389 E:394 ||| IN
cardinal  ||| S:394 E:403 ||| JJ
pain  ||| S:403 E:408 ||| NN
symptoms  ||| S:408 E:417 ||| NNS
of  ||| S:417 E:420 ||| IN
fibromyalgia  ||| S:420 E:433 ||| NNS
may  ||| S:433 E:437 ||| MD
be  ||| S:437 E:440 ||| VB
due  ||| S:440 E:444 ||| JJ
to  ||| S:444 E:447 ||| TO
alterations  ||| S:447 E:459 ||| VB
in  ||| S:459 E:462 ||| IN
central  ||| S:462 E:470 ||| JJ
processing  ||| S:470 E:481 ||| NN
of  ||| S:481 E:484 ||| IN
sensory  ||| S:484 E:492 ||| JJ
input ||| S:492 E:497 ||| NN
,  ||| S:497 E:499 ||| ,
along  ||| S:499 E:505 ||| RB
with  ||| S:505 E:510 ||| IN
aberrations  ||| S:510 E:522 ||| NN
in  ||| S:522 E:525 ||| IN
the  ||| S:525 E:529 ||| DT
endogenous  ||| S:529 E:540 ||| JJ
inhibition  ||| S:540 E:551 ||| NN
of  ||| S:551 E:554 ||| IN
pain ||| S:554 E:558 ||| NN
.  ||| S:558 E:560 ||| .
Genetic  ||| S:560 E:568 ||| JJ
research  ||| S:568 E:577 ||| NN
has  ||| S:577 E:581 ||| VBZ
shown  ||| S:581 E:587 ||| VBN
familial  ||| S:587 E:596 ||| JJ
aggregation  ||| S:596 E:608 ||| NN
of  ||| S:608 E:611 ||| IN
fibromyalgia  ||| S:611 E:624 ||| NN
and  ||| S:624 E:628 ||| CC
other  ||| S:628 E:634 ||| JJ
related  ||| S:634 E:642 ||| JJ
disorders  ||| S:642 E:652 ||| NNS
such  ||| S:652 E:657 ||| JJ
as  ||| S:657 E:660 ||| IN
major  ||| S:660 E:666 ||| JJ
depressive  ||| S:666 E:677 ||| JJ
disorder ||| S:677 E:685 ||| NN
.  ||| S:685 E:687 ||| .
Exposure  ||| S:687 E:696 ||| NN
to  ||| S:696 E:699 ||| TO
physical  ||| S:699 E:708 ||| JJ
or  ||| S:708 E:711 ||| CC
psychosocial  ||| S:711 E:724 ||| JJ
stressors ||| S:724 E:733 ||| NNS
,  ||| S:733 E:735 ||| ,
as  ||| S:735 E:738 ||| RB
well  ||| S:738 E:743 ||| RB
as  ||| S:743 E:746 ||| IN
abnormal  ||| S:746 E:755 ||| JJ
biologic  ||| S:755 E:764 ||| JJ
responses  ||| S:764 E:774 ||| NNS
in  ||| S:774 E:777 ||| IN
the  ||| S:777 E:781 ||| DT
autonomic  ||| S:781 E:791 ||| JJ
nervous  ||| S:791 E:799 ||| JJ
system  ||| S:799 E:806 ||| NN
and  ||| S:806 E:810 ||| CC
neuroendocrine  ||| S:810 E:825 ||| JJ
responses ||| S:825 E:834 ||| NNS
,  ||| S:834 E:836 ||| ,
may  ||| S:836 E:840 ||| MD
also  ||| S:840 E:845 ||| RB
contribute  ||| S:845 E:856 ||| VB
to  ||| S:856 E:859 ||| TO
dysfunctional  ||| S:859 E:873 ||| VB
pain  ||| S:873 E:878 ||| NN
processing ||| S:878 E:888 ||| NN
.  ||| S:888 E:890 ||| .
As  ||| S:890 E:893 ||| IN
fibromyalgia  ||| S:893 E:906 ||| JJ
research  ||| S:906 E:915 ||| NN
continues  ||| S:915 E:925 ||| VBZ
to  ||| S:925 E:928 ||| TO
progress ||| S:928 E:936 ||| VB
,  ||| S:936 E:938 ||| ,
it  ||| S:938 E:941 ||| PRP
is  ||| S:941 E:944 ||| VBZ
expected  ||| S:944 E:953 ||| VBN
that  ||| S:953 E:958 ||| IN
the  ||| S:958 E:962 ||| DT
pathophysiology  ||| S:962 E:978 ||| NN
of  ||| S:978 E:981 ||| IN
this  ||| S:981 E:986 ||| DT
disorder  ||| S:986 E:995 ||| NN
will  ||| S:995 E:1000 ||| MD
be  ||| S:1000 E:1003 ||| VB
further  ||| S:1003 E:1011 ||| JJ
elucidated ||| S:1011 E:1021 ||| NN
,  ||| S:1021 E:1023 ||| ,
leading  ||| S:1023 E:1031 ||| VBG
to  ||| S:1031 E:1034 ||| TO
more  ||| S:1034 E:1039 ||| RBR
rational  ||| S:1039 E:1048 ||| JJ
and  ||| S:1048 E:1052 ||| CC
targeted  ||| S:1052 E:1061 ||| JJ
strategies  ||| S:1061 E:1072 ||| NNS
for  ||| S:1072 E:1076 ||| IN
the  ||| S:1076 E:1080 ||| DT
treatment  ||| S:1080 E:1090 ||| NN
of  ||| S:1090 E:1093 ||| IN
patients  ||| S:1093 E:1102 ||| NNS
with  ||| S:1102 E:1107 ||| IN
this  ||| S:1107 E:1112 ||| DT
condition ||| S:1112 E:1121 ||| NN
.  ||| S:1121 E:1123 ||| .
